IPHA Lacutamab: $540M Sobi Deal Funds Phase 3

Innate Pharma (IPHA) has entered a strategic partnership with Swedish Orphan Biovitrum (Sobi) to advance lacutamab, a first-in-class anti-KIR3DL2 antibody, toward an accelerated approval filing in Sézary syndrome, a rare and aggressive subtype of cutaneous T-cell lymphoma. Sobi will pay $75 million upfront and up to $465 million in milestone payments for exclusive global commercialization rights. The deal enables initiation of the TELLOMAK-3 confirmatory Phase 3 study. IPHA shares closed at $1.73 on August 8 on thin ADR volume of just over 5,000 shares.

Lacutamab targets KIR3DL2, a killer immunoglobulin-like receptor expressed on malignant CD4+ T-cells in Sézary syndrome and mycosis fungoides. No therapy specifically targeting KIR3DL2 is approved. Sézary syndrome has roughly 3,000 patients in the US with a median survival under five years. Current options, including bexarotene, interferon, and extracorporeal photopheresis, are palliative and poorly tolerated.

Existing approved therapies for CTCL include mogamulizumab (anti-CCR4) and brentuximab vedotin for CD30-positive subtypes, but neither targets KIR3DL2 or was designed specifically for Sézary syndrome. Lacutamab’s mechanism addresses a different biology: it binds to KIR3DL2 and triggers antibody-dependent cell-mediated cytotoxicity, selectively depleting malignant T-cells while sparing normal immune function.

The deal structure reflects both the opportunity and the binary risk. The $75 million upfront is modest by oncology licensing standards, and the $465 million in milestone payments ties most of the deal value to clinical and regulatory success. Sobi can assume full global development rights after positive Phase 3 results, giving it an option to build a hematology-oncology franchise around lacutamab without committing to the full development cost upfront.

For Innate, the deal provides non-dilutive funding as access to capital tightens across biotech, and at a $1.73 stock price, the $75 million upfront represents meaningful operational runway without shareholder dilution. The company also announced the appointment of Dr. Arvind Sood as Chief Medical Officer on the same day, signaling an operational ramp-up ahead of TELLOMAK-3. Innate’s broader pipeline includes monalizumab (anti-NKG2A) in Phase 3 with AstraZeneca for non-small cell lung cancer and IPH4502, a Nectin-4 antibody-drug conjugate in early solid tumor development.

The risk: TELLOMAK-3 has not started, so any accelerated approval filing and revenue are years away. Sézary syndrome is a small market, and Sobi’s commercial infrastructure is built on rare hematology and immunology rather than oncology. The partnership validates KIR3DL2 biology but does not guarantee it works in a registrational trial. For more on evaluating clinical-stage biotechs, see the guide to reading clinical trial press releases.

Source: Sobi and Innate Pharma partnership announcement, August 10, 2026 · TELLOMAK Phase 2 on ClinicalTrials.gov (NCT03902184)